{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:20:55Z","timestamp":1792189255713,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2016J01616"],"award-info":[{"award-number":["2016J01616"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81502039"],"award-info":[{"award-number":["81502039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81502039"],"award-info":[{"award-number":["81502039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>5-Fluorouracil (5-FU) is one of the most effective drugs for the treatment of colorectal cancer (CRC). However, there is an urgent need in reducing its systemic side effects and chemoresistance to make 5-FU-based chemotherapy more effective and less toxic in the treatment of CRC. Here, enalapril, a clinically widely used antihypertensive and anti-heart failure drug, has been verified as a chemosensitizer that extremely improves the sensitivity of CRC cells to 5-FU. Enalapril greatly augmented the cytotoxicity of 5-FU on the cell growth in both established and primary CRC cells. The combination of enalapril and 5-FU synergistically suppressed the cell migration and invasion in both 5-FU-sensitive and -resistant CRC cells in vitro, and inhibited angiogenesis, tumor growth, and metastasis of 5-FU-resistant CRC cells in vivo without increased systemic toxicity at concentrations that were ineffective as individual agents. Furthermore, combined treatment cooperatively inhibited NF-\u03baB\/STAT3 signaling pathway and subsequently reduced the expression levels of NF-\u03baB\/STAT3-regulated proteins (c-Myc, Cyclin D1, MMP-9, MMP-2, VEGF, Bcl-2, and XIAP) in vitro and in vivo. This study provides the first evidence that enalapril greatly sensitized CRC cells to 5-FU at clinically achievable concentrations without additional toxicity and the synergistic effect may be mainly by cooperatively suppressing proliferation, angiogenesis, and NF-\u03baB\/STAT3-regulated proteins.<\/jats:p>","DOI":"10.1038\/s41419-020-2675-x","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T09:02:50Z","timestamp":1592989370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-\u03baB\/STAT3-regulated proteins"],"prefix":"10.1038","volume":"11","author":[{"given":"Yushan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"2675_CR1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3322\/caac.21395","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel, R. L. et al. Colorectal cancer statistics, 2017. CA Cancer J. Clin. 67, 177\u2013193 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"2675_CR2","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters, M. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 4706\u20134713 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2675_CR3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/CAD.0000000000000546","volume":"28","author":"C Vazquez","year":"2017","unstructured":"Vazquez, C. et al. Prediction of severe toxicity in adult patients under treatment with 5-fluorouracil: a prospective cohort study. Anticancer Drugs 28, 1039\u20131046 (2017).","journal-title":"Anticancer Drugs"},{"key":"2675_CR4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-2125.2010.03892.x","volume":"72","author":"B Pardini","year":"2011","unstructured":"Pardini, B. et al. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR\/MTRR genotypes. Br. J. Clin. Pharmacol. 72, 162\u2013163 (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"2675_CR5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.clcc.2016.04.001","volume":"15","author":"M Wilhelm","year":"2016","unstructured":"Wilhelm, M. et al. Prospective, multicenter study of 5-fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice. Clin. Colorectal Cancer 15(4), 381\u2013388 (2016).","journal-title":"Clin. Colorectal Cancer"},{"key":"2675_CR6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330\u2013338 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"2675_CR7","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale, D. et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114, 2474\u20132481 (2006).","journal-title":"Circulation"},{"key":"2675_CR8","first-page":"1227","volume":"20","author":"H Yoshiji","year":"2002","unstructured":"Yoshiji, H. et al. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int. J. Oncol. 20, 1227\u20131231 (2002).","journal-title":"Int. J. Oncol."},{"key":"2675_CR9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11010-010-0400-2","volume":"340","author":"J Yang","year":"2010","unstructured":"Yang, J. et al. CBP knockdown inhibits angiotensin II-induced vascular smooth muscle cells proliferation through downregulating NF-kB transcriptional activity. Mol. Cell. Biochem. 340, 55\u201362 (2010).","journal-title":"Mol. Cell. Biochem."},{"key":"2675_CR10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","volume":"352","author":"AF Lever","year":"1998","unstructured":"Lever, A. F. et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352, 179\u2013184 (1998).","journal-title":"Lancet"},{"key":"2675_CR11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2004.06.022","volume":"22","author":"JH Silber","year":"2004","unstructured":"Silber, J. H. et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol. 22, 820\u2013828 (2004).","journal-title":"J. Clin. Oncol."},{"key":"2675_CR12","first-page":"1073","volume":"7","author":"H Yoshiji","year":"2001","unstructured":"Yoshiji, H. et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res. 7, 1073\u20131078 (2001).","journal-title":"Clin. Cancer Res."},{"key":"2675_CR13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/gut.2009.188961","volume":"59","author":"V Fendrich","year":"2010","unstructured":"Fendrich, V. et al. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 59, 630\u2013637 (2010).","journal-title":"Gut"},{"key":"2675_CR14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148323","volume":"11","author":"MM Wieck","year":"2016","unstructured":"Wieck, M. M. et al. Sequestration of Vascular Endothelial Growth Factor (VEGF) Induces Late Restrictive Lung Disease. PLoS ONE 11, e0148323 (2016).","journal-title":"PLoS ONE"},{"key":"2675_CR15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","volume":"82","author":"J Folkman","year":"1990","unstructured":"Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 82, 4\u20136 (1990).","journal-title":"J. Natl Cancer Inst."},{"key":"2675_CR16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrc1588","volume":"5","author":"C Nakanishi","year":"2005","unstructured":"Nakanishi, C. & Toi, M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 5, 297\u2013309 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"2675_CR17","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-06-4257","volume":"67","author":"AB Kunnumakkara","year":"2007","unstructured":"Kunnumakkara, A. B., Guha, S., Krishnan, S., Diagaradjane, P., Gelovani, J. & Aggarwal, B. B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. 67, 3853\u20133861 (2007).","journal-title":"Cancer Res."},{"key":"2675_CR18","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.1158\/0008-5472.CAN-10-4660","volume":"71","author":"L Lin","year":"2011","unstructured":"Lin, L. et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 71, 7226\u20137237 (2011).","journal-title":"Cancer Res."},{"key":"2675_CR19","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3892\/ijo.2017.3846","volume":"50","author":"B Li","year":"2017","unstructured":"Li, B. & Huang, C. Regulation of EMT by STAT3 in gastrointestinal cancer (Review). Int. J. Oncol. 50, 753\u2013767 (2017).","journal-title":"Int. J. Oncol."},{"key":"2675_CR20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2009.02.015","volume":"15","author":"H Lee","year":"2009","unstructured":"Lee, H. et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15, 283\u2013293 (2009).","journal-title":"Cancer Cell"},{"key":"2675_CR21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nm.2999","volume":"19","author":"M Bruchard","year":"2013","unstructured":"Bruchard, M. et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 19, 57\u201364 (2013).","journal-title":"Nat. Med."},{"key":"2675_CR22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s13046-019-1314-9","volume":"38","author":"Q Zhang","year":"2019","unstructured":"Zhang, Q. et al. Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells. J. Exp. Clin. Cancer Res. 38, 320 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2675_CR23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/02841860500417486","volume":"45","author":"P Albertsson","year":"2006","unstructured":"Albertsson, P., Lennernas, B. & Norrby, K. On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A. Acta Oncol. 45, 144\u2013155 (2006).","journal-title":"Acta Oncol."},{"key":"2675_CR24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/02841860802409512","volume":"48","author":"P Albertsson","year":"2009","unstructured":"Albertsson, P., Lennernas, B. & Norrby, K. Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis. Acta Oncol. 48, 418\u2013425 (2009).","journal-title":"Acta Oncol."},{"key":"2675_CR25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.biopha.2014.05.004","volume":"68","author":"S Namazi","year":"2014","unstructured":"Namazi, S., Rostami-Yalmeh, J., Sahebi, E., Jaberipour, M., Razmkhah, M. & Hosseini, A. The role of captopril and losartan in prevention and regression of tamoxifen-induced resistance of breast cancer cell line MCF-7: An in vitro study. Biomed. Pharmacother. 68, 565\u2013571 (2014).","journal-title":"Biomed. Pharmacother."},{"key":"2675_CR26","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/sj.bjc.6605955","volume":"103","author":"Y Nakai","year":"2010","unstructured":"Nakai, Y. et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br. J. Cancer 103, 1644\u20131648 (2010).","journal-title":"Br. J. Cancer"},{"key":"2675_CR27","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00432-009-0587-3","volume":"135","author":"S Wilop","year":"2009","unstructured":"Wilop, S., von Hobe, S., Crysandt, M., Esser, A., Osieka, R. & Jost, E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J. Cancer Res. Clin. Oncol. 135, 1429\u20131435 (2009).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2675_CR28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrc822","volume":"2","author":"JP Thiery","year":"2002","unstructured":"Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442\u2013454 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"2675_CR29","doi-asserted-by":"crossref","unstructured":"Parikh, A. R. et al. MAVERICC, a randomized, biomarker-stratified, phase II study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as first-line chemotherapy in metastatic colorectal cancer. Clin. Cancer Res. 25, 2988\u20132995 (2018).","DOI":"10.1158\/1078-0432.CCR-18-1221"},{"key":"2675_CR30","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1200\/JCO.2009.25.2106","volume":"28","author":"V Boige","year":"2010","unstructured":"Boige, V. et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J. Clin. Oncol. 28, 2556\u20132564 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2675_CR31","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.2012.42.4044","volume":"30","author":"LE McCahill","year":"2012","unstructured":"McCahill, L. E. et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J. Clin. Oncol. 30, 3223\u20133228 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2675_CR32","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","volume":"13","author":"A de Gramont","year":"2012","unstructured":"de Gramont, A. et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 13, 1225\u20131233 (2012).","journal-title":"Lancet Oncol."},{"key":"2675_CR33","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00228-014-1755-1","volume":"70","author":"C Biagi","year":"2014","unstructured":"Biagi, C. et al. Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions. Eur. J. Clin. Pharmacol. 70, 1505\u20131512 (2014).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2675_CR34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1053\/j.gastro.2010.05.030","volume":"139","author":"GK Lau","year":"2010","unstructured":"Lau, G. K. & Ye, D. STAT3 implicated in the development of colon cancer: a step closer for targeted therapy? Gastroenterology 139, 353\u2013355 (2010).","journal-title":"Gastroenterology"},{"key":"2675_CR35","doi-asserted-by":"crossref","unstructured":"Taniguchi, K. & Karin, M. NF-kappaB, inflammation, immunity and cancer: coming of age. Nat. Rev. Immunol. 18, 309\u2013324 (2018).","DOI":"10.1038\/nri.2017.142"},{"key":"2675_CR36","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ccell.2018.07.004","volume":"34","author":"R Schulz-Heddergott","year":"2018","unstructured":"Schulz-Heddergott, R. et al. Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion. Cancer Cell 34, 298\u2013314 e297 (2018).","journal-title":"Cancer Cell"},{"key":"2675_CR37","volume":"9","author":"BD Wang","year":"2010","unstructured":"Wang, B. D. et al. Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. Mol. Cancer 9, 98 (2010).","journal-title":"Mol. Cancer"},{"key":"2675_CR38","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611\u2013629 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2675_CR39","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrc.2017.118","volume":"18","author":"T Brabletz","year":"2018","unstructured":"Brabletz, T., Kalluri, R., Nieto, M. A. & Weinberg, R. A. EMT in cancer. Nat. Rev. Cancer 18, 128\u2013134 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"2675_CR40","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/carcin\/bgv017","volume":"36","author":"H Liu","year":"2015","unstructured":"Liu, H. et al. Aberrantly expressed Fra-1 by IL-6\/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition. Carcinogenesis 36, 459\u2013468 (2015).","journal-title":"Carcinogenesis"},{"key":"2675_CR41","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/ijc.31232","volume":"142","author":"W Liu","year":"2018","unstructured":"Liu, W., Wang, S., Sun, Q., Yang, Z., Liu, M. & Tang, H. DCLK1 promotes epithelial-mesenchymal transition via the PI3K\/Akt\/NF-kappaB pathway in colorectal cancer. Int. J. Cancer 142, 2068\u20132079 (2018).","journal-title":"Int. J. Cancer"},{"key":"2675_CR42","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1172\/JCI73531","volume":"124","author":"M Rokavec","year":"2014","unstructured":"Rokavec, M. et al. IL-6R\/STAT3\/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J. Clin. Investig. 124, 1853\u20131867 (2014).","journal-title":"J. Clin. Investig."},{"key":"2675_CR43","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2147\/OTT.S159093","volume":"11","author":"X Meng","year":"2018","unstructured":"Meng, X. & Fu, R. miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells. OncoTargets Ther. 11, 1757\u20131765 (2018).","journal-title":"OncoTargets Ther."},{"key":"2675_CR44","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ajh.21840","volume":"85","author":"P Georgakopoulos","year":"2010","unstructured":"Georgakopoulos, P. et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am. J. Hematol. 85, 894\u2013896 (2010).","journal-title":"Am. J. Hematol."},{"key":"2675_CR45","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2013.07.077","volume":"62","author":"P Spallarossa","year":"2013","unstructured":"Spallarossa, P., Guerrini, M., Arboscello, E. & Sicbaldi, V. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 62, 2451\u20132452 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2675_CR46","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Oncotarget 6, 9999\u201310015 (2015).","DOI":"10.18632\/oncotarget.3171"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2675-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2675-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2675-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T15:07:34Z","timestamp":1670252854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2675-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["2675"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-2675-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"assertion":[{"value":"21 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"477"}}